@article{Harji_D-2021_206588,
title = {Rectal cancer management during the COVID-19 pandemic (ReCaP): multicentre prospective observational study},
author = {Harji, D. and Poynter, L. and Jackson, R. and Adams, R. and Vimalachandran, D. and Clifford, R. and Fearnhead, N. and ReCaP Steering Committee and Collaborators},
month = {may},
year = {2021},
abstract = {Over 8000 patients are diagnosed with rectal cancer in the UK each year. Treatment has improved over recent years as a result of incremental advances in optimized surgical technique, clinical staging, pathological quality control, and multidisciplinary management. Neoadjuvant therapy is often required in patients with locally advanced tumours, and is usually delivered according to a long-course strategy (long-course radiotherapy, LCRT). Hypofractionated short-course strategies (short-course radiotherapy, SCRT) may also be used, traditionally with immediate surgery, but recently have been combined with strategies such as delayed surgery and/or systemic chemotherapy. Such regimens offer potential benefits for patients in terms of reducing treatment time and access to systemic therapy, but may also be of use in areas with limited healthcare resources or geographical access to specialist services.},
pages = {1270-1273},
volume = {108},
issue = {11},
journal = {British Journal of Surgery},
publisher = {Oxford University Press},
url = {https://doi.org/10.1093/bjs/znab129},
}
